<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098460</url>
  </required_header>
  <id_info>
    <org_study_id>260-13-806-01</org_study_id>
    <nct_id>NCT02098460</nct_id>
  </id_info>
  <brief_title>To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of concomitant administration of Probucol and Cilostazol (based on
      Atorvastatin treatment) on the atherosclerosis related markers (including the thickness of
      the Achilles tendon) in severe hypercholesterolemia subject, through the observation of the
      thickness of the Achilles tendon, the thickness of mean carotid intima-media, anti-oxidation
      biomarkers and serum lipid profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, controlled, single-blinded, three parallel arms study. Group A:
      Atorvastatin + Probucol-placebo + Cilostazol-placebo Group B: Atorvastatin + Probucol +
      Cilostazol-placebo Group C: Atorvastatin + Probucol + Cilostazol
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effect of concomitant administration of Probucol and Cilostazol on the mean achilles tendon thickness (ATT)</measure>
    <time_frame>at Month 6, 12 and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the additional effect of concomitant administration of Probucol and Cilostazol on mean carotid intima-media thickness (IMT)</measure>
    <time_frame>at Month 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the preventive effect of concomitant administration of Probucol and Cilostazol on the incidence of cerebrovascular and cardiovascular events (including intervention)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the effect of concomitant administration of Probucol and Cilostazol on biomarkers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the safety of Probucol or concomitant administration of Probucol and Cilostazol as determined by physical examination, vital signs, adverse events (AEs), laboratory examinations and 12-lead electrocardiogram (ECGs)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Severe Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Probucol,Cilostazol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin + Probucol-placebo + Cilostazol-placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin + Probucol+ Cilostazol-placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probucol, Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin + Probucol + Cilostazol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin, Probucol, Cilostazol</intervention_name>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_label>Probucol, Cilostazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject whose voluntary written informed consent is obtained for participation in
             this study;

          2. 18≤age≤70；

          3. The subject with low-density lipoprotein cholesterol (LDL-C) ≥ 4.66 mmol/L (180 mg/dL)
             (the highest level either pre-treatment or on treatment);

          4. The subject with ATT≥9mm.

        Exclusion Criteria:

          1. The subject with homozygous familial hyperlipidemia;

          2. The subject who took Probucol within 6 months before the screening test;

          3. The subject who took Cilostazol within 1 month before the screening test;

          4. The subject who took Ezetimibe within 1 month before the screening test;

          5. The subject who hoped to treat with Ezetimibe within this study period;

          6. The subject being treated with Cyclosporine;

          7. The subject with a history of hypersensitivity to Probucol and Cilostazol;

          8. The subject with a triglyceride (TG) level greater than 4.52 mmol/L (400 mg/dL);

          9. The subject with diabetes: HbA1c level greater than 8.4% (NGSP);

         10. The subject with New York Heart Association (NYHA) classification: Class III and IV;

         11. The subject with a QTc interval greater than 450 msec (male) or 470 msec (female);

         12. The subject with serious ventricular arrythmias (frequent episodes of multifocal
             ventricular extrasystole);

         13. The subject with atrial fibrillation (including paroxysmal atrial fibrillation);

         14. The subject with congestive cardiac failure or unstable angina;

         15. The subject with liver and renal functions that satisfy the following criteria within
             28 days prior to start of the investigational medicinal product (IMP) administration.

               -  AST ≥100 IU/L, ALT≥100 IU/L

               -  Serum creatinine ≥1.5 mg/dL (133 µmol/L)

         16. The subject who are participating in another clinical trial;

         17. Woman during pregnancy or potential pregnancy, and breastfeeding;

         18. Women of childbearing potential who are not agree to use an appropriate method of
             contraception;

         19. The subject who are not considered by the Investigators to be appropriate to
             participate in this study for any other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Lin, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anzhen hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anzhen hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Lin, Dr</last_name>
      <phone>00861064412431</phone>
    </contact>
    <investigator>
      <last_name>Jie Lin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>the Achilles tendon</keyword>
  <keyword>intima-media thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Probucol</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

